Skip to main content

Table 4 Characteristics of pediatric critically ill patients with MDR-Gram negative organism with Intravenous polymyxin B use

From: Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study

Characteristics n = 14 n(%)
Age median (range) 7 month ( 1 month - 12 yrs)
Gender  
  Males 7(50%)
Underlying disease  
  CVS 8(57.1%)
  CNS 4(28.6%
  Respiratory 2(14.3%)
Site of infection  
  Respiratory 11(78.6%)
  BSI 1(7.1%)
  BSI + Respiratory 2(14.3%)
Isolated organisms in Blood (n = 3)  
  Acinetobacter Species 1
  Pseudomonas Aeruginosa 1
  Klebsiella Pneumoniae 1
Isolated organisms in respiratory secretions (n = 15)  
  Acinetobacter Species 9
  Pseudomonas Aeruginosa 4
  Klebsiella Pneumoniae 1
  Enterobacter species 1
Antibiotics used prior to Polymyxin B Ceftriaxone, Meropenem, Vancomycin
Antibiotics used concomitantly with Polymyxin B Meropenem, Vancomycin, Tobramycin, Ciprofloxacin
PICU stay before instillation of IV Polymyxin B in days median (range) 7.0(1–17 days)
Duration of IV Polymyxin B treatment in days median (range) 8.5(2–14 days)
Dosage of Polymyxin B 40,000 IU/kg/day
Nephrotoxicity 3(21.4%)
Serum creatinine before Polymyxin B use (mg/dl) median (range) 0.41(0.1-1.2)
Serum creatinine after Polymyxin B use (mg/dl) median (range) 0.55(0.1-1.6)
Neurotoxicity 0
Outcome  
  Expired 6(42.9%)
  Survived 8(57.1%)